KR102057508B1 - 혈청 인을 조절하는 치료제 - Google Patents

혈청 인을 조절하는 치료제 Download PDF

Info

Publication number
KR102057508B1
KR102057508B1 KR1020137034736A KR20137034736A KR102057508B1 KR 102057508 B1 KR102057508 B1 KR 102057508B1 KR 1020137034736 A KR1020137034736 A KR 1020137034736A KR 20137034736 A KR20137034736 A KR 20137034736A KR 102057508 B1 KR102057508 B1 KR 102057508B1
Authority
KR
South Korea
Prior art keywords
variant
xaa xaa
xaa
mod
res
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137034736A
Other languages
English (en)
Korean (ko)
Other versions
KR20140035456A (ko
Inventor
펠릭스 카림
그레고리 벨
Original Assignee
카이 파마슈티컬즈
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카이 파마슈티컬즈 filed Critical 카이 파마슈티컬즈
Publication of KR20140035456A publication Critical patent/KR20140035456A/ko
Application granted granted Critical
Publication of KR102057508B1 publication Critical patent/KR102057508B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
KR1020137034736A 2011-06-08 2012-06-08 혈청 인을 조절하는 치료제 Active KR102057508B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161494874P 2011-06-08 2011-06-08
US61/494,874 2011-06-08
PCT/US2012/041759 WO2012170955A1 (en) 2011-06-08 2012-06-08 Therapeutic agents for regulating serum phosphorus

Publications (2)

Publication Number Publication Date
KR20140035456A KR20140035456A (ko) 2014-03-21
KR102057508B1 true KR102057508B1 (ko) 2019-12-19

Family

ID=46321485

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137034736A Active KR102057508B1 (ko) 2011-06-08 2012-06-08 혈청 인을 조절하는 치료제

Country Status (23)

Country Link
US (1) US8969299B2 (https=)
EP (1) EP2717896B1 (https=)
JP (1) JP5982473B2 (https=)
KR (1) KR102057508B1 (https=)
CN (1) CN103857405B (https=)
AU (1) AU2012267470C1 (https=)
BR (1) BR112013031539A2 (https=)
CA (1) CA2837445C (https=)
CY (1) CY1118430T1 (https=)
DK (1) DK2717896T3 (https=)
ES (1) ES2607986T3 (https=)
HR (1) HRP20161566T1 (https=)
HU (1) HUE032087T2 (https=)
LT (1) LT2717896T (https=)
MX (1) MX337613B (https=)
PL (1) PL2717896T3 (https=)
PT (1) PT2717896T (https=)
RS (1) RS55503B1 (https=)
RU (1) RU2612912C2 (https=)
SG (1) SG195290A1 (https=)
SI (1) SI2717896T1 (https=)
SM (2) SMT201700081T1 (https=)
WO (1) WO2012170955A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2729051T3 (es) 2009-07-29 2019-10-30 Kai Pharmaceuticals Inc Agentes terapéuticos para reducir los niveles de hormona paratiroidea
SMT201700401T1 (it) 2013-06-28 2017-09-07 Amgen Inc Formulazione liquida stabile di amg 416 (velcalcetide)
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
CN114222578B (zh) * 2019-12-09 2024-06-25 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
KR20230066044A (ko) * 2020-09-10 2023-05-12 샨시 마이콧 테크놀로지 컴퍼니 리미티드 이중특이적 융합 폴리펩타이드 화합물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014707A2 (en) * 2009-07-29 2011-02-03 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
AU9131091A (en) 1990-11-07 1992-06-11 Scripps Research Institute, The Peptides that inhibit platelet binding of adhesion molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1995006056A1 (en) 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5895368A (en) * 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
WO1998017299A1 (en) 1996-10-18 1998-04-30 The Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase c, methods and compositions
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
JP2000336099A (ja) 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びｃ型肝炎抗体検出用試薬
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
EP1301479A2 (en) 2000-07-18 2003-04-16 Bone Care International, Inc. STABILIZED 1$g(a)-HYDROXY VITAMIN D
US20080249016A1 (en) 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
WO2002057413A2 (en) 2001-01-18 2002-07-25 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of delta pkc
WO2002062396A2 (en) 2001-02-08 2002-08-15 University Of Medicine And Dentistry Of New Jersey Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
ES2527339T3 (es) 2001-02-23 2015-01-23 Polyphor Ltd. Peptidomiméticos fijados a patrón con actividad antimicrobiana
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
US20040018976A1 (en) 2002-05-14 2004-01-29 Feder John N. Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof
WO2004093821A2 (en) 2003-04-22 2004-11-04 Hawaii Biotech, Inc. Treatment of anthrax infection using inhibitors of lethal factor protease activity
CA2543072A1 (en) 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
JP2007513974A (ja) 2003-12-11 2007-05-31 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー プロテインキナーゼｃのアイソザイム特異的アンタゴニスト
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
JP2009511426A (ja) 2005-08-30 2009-03-19 アコロジックス インコーポレイティッド ミネラルおよび骨格代謝の調節
WO2007038172A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
JP5645408B2 (ja) * 2006-11-16 2014-12-24 カイ ファーマシューティカルズ インコーポレーティッド 副甲状腺機能亢進症および高カルシウム血症性障害の治療のためのポリカチオン性カルシウムモジュレーターペプチド
KR20090115852A (ko) 2007-01-19 2009-11-09 카이 파마슈티컬즈 안정성 및 전달 효율을 증가시키기 위한 펩타이드 조성물의 변형
CA2701274A1 (en) 2007-10-02 2009-04-09 Mdrna, Inc. Lipopeptides for delivery of nucleic acids
EP2229473A4 (en) 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011014707A2 (en) * 2009-07-29 2011-02-03 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nephrology Dialysis Transplantation. Vol. 22, No. 6, pp. 1639-1644 (2007) 1부.*

Also Published As

Publication number Publication date
DK2717896T3 (en) 2016-12-19
RU2612912C2 (ru) 2017-03-13
ES2607986T3 (es) 2017-04-05
RS55503B1 (sr) 2017-05-31
MX337613B (es) 2016-03-10
WO2012170955A1 (en) 2012-12-13
AU2012267470B2 (en) 2017-06-15
US20130150301A1 (en) 2013-06-13
PT2717896T (pt) 2016-12-23
SI2717896T1 (sl) 2017-04-26
KR20140035456A (ko) 2014-03-21
CY1118430T1 (el) 2017-06-28
SG195290A1 (en) 2013-12-30
CA2837445A1 (en) 2012-12-13
AU2012267470C1 (en) 2017-09-21
CN103857405B (zh) 2015-12-02
LT2717896T (lt) 2017-02-27
CN103857405A (zh) 2014-06-11
HRP20161566T1 (hr) 2017-02-24
EP2717896A1 (en) 2014-04-16
BR112013031539A2 (pt) 2019-07-30
MX2013014249A (es) 2014-01-24
PL2717896T3 (pl) 2017-05-31
JP2014522414A (ja) 2014-09-04
HUE032087T2 (en) 2017-08-28
SMT201700081B (it) 2017-03-08
CA2837445C (en) 2022-10-04
EP2717896B1 (en) 2016-08-24
US8969299B2 (en) 2015-03-03
SMT201700081T1 (it) 2017-03-08
RU2013157928A (ru) 2015-07-20
JP5982473B2 (ja) 2016-08-31

Similar Documents

Publication Publication Date Title
US20250163103A1 (en) Therapeutic agents for reducing parathyroid hormone levels
JP6204369B2 (ja) カルシウム模倣薬およびその使用方法
TW202317604A (zh) 用於治療遺傳性血鐵沉積症之鐵調素模擬物
KR102057508B1 (ko) 혈청 인을 조절하는 치료제
AU2012267470A1 (en) Therapeutic agents for regulating serum phosphorus
JP7796013B2 (ja) カルシウム感知受容体アゴニスト化合物及びその使用
WO2022052471A1 (zh) 双特异性融合多肽化合物
HK1196939B (en) Therapeutic agents for regulating serum phosphorus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20131227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170320

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180717

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190220

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180717

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20190220

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20181011

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190423

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20190925

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20190822

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190321

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190220

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20181011

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20191213

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20191216

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20221123

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20221123

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20231128

Start annual number: 5

End annual number: 5